NASDAQ:OCUL - Ocular Therapeutix Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$6.79 -0.10 (-1.45 %)
(As of 05/22/2018 01:12 PM ET)
Previous Close$6.81
Today's Range$6.79 - $6.95
52-Week Range$3.30 - $11.79
Volume7,940 shs
Average Volume251,406 shs
Market Capitalization$258.35 million
P/E Ratio-3.10
Dividend YieldN/A
Beta1.25

About Ocular Therapeutix (NASDAQ:OCUL)

Ocular Therapeutix logoOcular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. Its lead product candidates include DEXTENZA (dexamethasone insert) for the treatment of post-surgical ocular pain and inflammation, allergic conjunctivitis, and dry eye diseases; and OTX-TP (travoprost insert) for the reduction of intraocular pressure (IOP) in patients with glaucoma and ocular hypertension. The company is also developing OTX-TIC, an intracameral travoprost implant for the reduction of IOP in patients with moderate to severe glaucoma and ocular hypertension; and OTX-TKI, a tyrosine kinase inhibitor intravitreal injection that delivers a hydrogel-based anti-angiogenic formulation for the treatment of wet age-related macular degeneration. In addition, it markets ReSure Sealant, a hydrogel-based ophthalmic wound sealant to seal corneal incisions following cataract surgery. Further, the company engages in the preclinical development of formulations of its hydrogel administered via intravitreal injection to address the diseases and conditions of the back of the eye. Ocular Therapeutix, Inc. has collaboration agreement with Regeneron Pharmaceuticals, Inc. for the development and commercialization of products using its hydrogel in combination with large molecule VEGF-targeting compounds for the treatment of retinal diseases. The company was founded in 2006 and is headquartered in Bedford, Massachusetts.

Receive OCUL News and Ratings via Email

Sign-up to receive the latest news and ratings for OCUL and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:OCUL
CUSIPN/A
Phone781-357-4000

Debt

Debt-to-Equity Ratio0.22
Current Ratio4.90
Quick Ratio4.89

Price-To-Earnings

Trailing P/E Ratio-3.10
Forward P/E Ratio-3.55
P/E GrowthN/A

Sales & Book Value

Annual Sales$1.92 million
Price / Sales131.84
Cash FlowN/A
Price / CashN/A
Book Value$0.72 per share
Price / Book9.43

Profitability

EPS (Most Recent Fiscal Year)($2.20)
Net Income$-63,380,000.00
Net Margins-3,418.79%
Return on Equity-153.53%
Return on Assets-88.54%

Miscellaneous

Employees119
Outstanding Shares37,280,000

Ocular Therapeutix (NASDAQ:OCUL) Frequently Asked Questions

What is Ocular Therapeutix's stock symbol?

Ocular Therapeutix trades on the NASDAQ under the ticker symbol "OCUL."

How were Ocular Therapeutix's earnings last quarter?

Ocular Therapeutix (NASDAQ:OCUL) posted its earnings results on Tuesday, May, 8th. The biopharmaceutical company reported ($0.40) earnings per share for the quarter, missing analysts' consensus estimates of ($0.38) by $0.02. The biopharmaceutical company had revenue of $0.34 million for the quarter. Ocular Therapeutix had a negative return on equity of 153.53% and a negative net margin of 3,418.79%. View Ocular Therapeutix's Earnings History.

When is Ocular Therapeutix's next earnings date?

Ocular Therapeutix is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for Ocular Therapeutix.

What price target have analysts set for OCUL?

5 brokerages have issued twelve-month price objectives for Ocular Therapeutix's stock. Their predictions range from $8.00 to $22.00. On average, they anticipate Ocular Therapeutix's share price to reach $13.00 in the next year. View Analyst Ratings for Ocular Therapeutix.

What are Wall Street analysts saying about Ocular Therapeutix stock?

Here are some recent quotes from research analysts about Ocular Therapeutix stock:
  • 1. According to Zacks Investment Research, "Ocular Therapeutix, Inc. is a biopharmaceutical company. It is focused on the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology to address unmet or underserved needs in ophthalmology. The Company develops and markets eye care products. Ocular Therapeutix, Inc. is headquartered in Bedford, Massachusetts. " (5/12/2018)
  • 2. BTIG Research analysts commented, "On Thursday, before market open, the management team of Ocular Therapeutix hosted their 4Q17 earnings call. We think the updates provided on the call were in line with expectations. The company expects to resubmit the Dextenza NDA during 1H2018, with an FDA decision likely by YE2018. Key leadership positions have also been filled including the hiring of experienced quality and regulatory personnel, which we think could further provide additional investor confidence moving forward. We reiterate our Buy rating and $9 Price Target." (3/11/2018)
  • 3. Cantor Fitzgerald analysts commented, "Potential Approval before The End of The Year. After receiving feedback earlier this year, Ocular believes the complete and clear nature of the FDA’s responses removes the need for a meeting to obtain additional feedback. Currently, the company is conducting on-going manufacturing runs in order to establish and support confidence limits for particulate observed. Based on the focus on manufacturing, we anticipate a Type 2 review, consistent with a manufacturing inspection and six month review timeline." (3/8/2018)

Who are some of Ocular Therapeutix's key competitors?

Who are Ocular Therapeutix's key executives?

Ocular Therapeutix's management team includes the folowing people:
  • Dr. Amarpreet Sawhney, Founder & Exec. Chairman (Age 51)
  • Mr. Antony Mattessich, Pres, CEO & Director (Age 51)
  • Mr. Donald Notman Jr., Chief Financial Officer
  • Dr. Michael H. Goldstein, Chief Medical Officer (Age 51)
  • Mr. Kevin F. Hanley, Sr. VP of Technical Operations (Age 56)

Has Ocular Therapeutix been receiving favorable news coverage?

Media headlines about OCUL stock have been trending positive this week, Accern Sentiment Analysis reports. The research group identifies negative and positive media coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Ocular Therapeutix earned a news impact score of 0.47 on Accern's scale. They also gave news articles about the biopharmaceutical company an impact score of 46.45 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.

Who are Ocular Therapeutix's major shareholders?

Ocular Therapeutix's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Summer Road LLC (8.12%), BlackRock Inc. (4.55%), Deltec Asset Management LLC (1.57%), Northern Trust Corp (0.87%), Schwab Charles Investment Management Inc. (0.14%) and California State Teachers Retirement System (0.12%). Company insiders that own Ocular Therapeutix stock include Amarpreet Sawhney, Antony C Mattessich, Daniel M Bollag and Donald Notman. View Institutional Ownership Trends for Ocular Therapeutix.

Which institutional investors are selling Ocular Therapeutix stock?

OCUL stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN. View Insider Buying and Selling for Ocular Therapeutix.

Which institutional investors are buying Ocular Therapeutix stock?

OCUL stock was acquired by a variety of institutional investors in the last quarter, including Summer Road LLC, Deltec Asset Management LLC, BlackRock Inc., Northern Trust Corp, Barclays PLC, Millennium Management LLC, The Manufacturers Life Insurance Company and GSA Capital Partners LLP. Company insiders that have bought Ocular Therapeutix stock in the last two years include Amarpreet Sawhney, Antony C Mattessich, Daniel M Bollag and Donald Notman. View Insider Buying and Selling for Ocular Therapeutix.

How do I buy shares of Ocular Therapeutix?

Shares of OCUL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ocular Therapeutix's stock price today?

One share of OCUL stock can currently be purchased for approximately $6.82.

How big of a company is Ocular Therapeutix?

Ocular Therapeutix has a market capitalization of $258.35 million and generates $1.92 million in revenue each year. The biopharmaceutical company earns $-63,380,000.00 in net income (profit) each year or ($2.20) on an earnings per share basis. Ocular Therapeutix employs 119 workers across the globe.

How can I contact Ocular Therapeutix?

Ocular Therapeutix's mailing address is 15 CROSBY DRIVE, BEDFORD MA, 01730. The biopharmaceutical company can be reached via phone at 781-357-4000 or via email at [email protected]


MarketBeat Community Rating for Ocular Therapeutix (OCUL)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  214 (Vote Outperform)
Underperform Votes:  119 (Vote Underperform)
Total Votes:  333
MarketBeat's community ratings are surveys of what our community members think about Ocular Therapeutix and other stocks. Vote "Outperform" if you believe OCUL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OCUL will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Ocular Therapeutix (NASDAQ:OCUL) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
5 Wall Street analysts have issued ratings and price targets for Ocular Therapeutix in the last 12 months. Their average twelve-month price target is $13.00, suggesting that the stock has a possible upside of 91.46%. The high price target for OCUL is $22.00 and the low price target for OCUL is $8.00. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.802.802.832.67
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $13.00$13.00$20.6667$20.6667
Price Target Upside: 91.46% upside120.34% upside273.04% upside295.91% upside

Ocular Therapeutix (NASDAQ:OCUL) Consensus Price Target History

Price Target History for Ocular Therapeutix (NASDAQ:OCUL)

Ocular Therapeutix (NASDAQ:OCUL) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/9/2018HC WainwrightSet Price TargetBuy$10.00HighView Rating Details
5/8/2018Cantor FitzgeraldSet Price TargetBuy$22.00HighView Rating Details
3/11/2018BTIG ResearchReiterated RatingBuyHighView Rating Details
10/23/2017GuggenheimInitiated CoverageBuy$12.00N/AView Rating Details
7/14/2017Morgan StanleyReiterated RatingEqual Weight$16.00 ➝ $8.00LowView Rating Details
3/13/2017CowenReiterated RatingOutperform$60.00MediumView Rating Details
11/15/2016Royal Bank of CanadaReiterated RatingOutperform$30.00 ➝ $32.00N/AView Rating Details
8/11/2016JMP SecuritiesInitiated CoverageOutperform$21.00 ➝ $5.84N/AView Rating Details
(Data available from 5/22/2016 forward)

Earnings

Ocular Therapeutix (NASDAQ:OCUL) Earnings History and Estimates Chart

Earnings by Quarter for Ocular Therapeutix (NASDAQ:OCUL)

Ocular Therapeutix (NASDAQ:OCUL) Earnings Estimates

Current Year EPS Consensus Estimate: $-1.91 EPS
Next Year EPS Consensus Estimate: $-1.4 EPS

Ocular Therapeutix (NASDAQ OCUL) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/6/2018($0.37)N/AView Earnings Details
5/8/2018Q1 2018($0.38)($0.40)$0.34 millionViewN/AView Earnings Details
3/8/2018Q4 2017($0.58)($0.44)$0.51 million$0.50 millionViewN/AView Earnings Details
11/7/2017Q3 2017($0.54)($0.54)$0.52 million$523.00 millionViewN/AView Earnings Details
8/8/2017Q2 2017($0.59)($0.64)$0.51 million$0.40 millionViewListenView Earnings Details
5/5/2017Q1 2017($0.4830)($0.58)$0.51 million$0.48 millionViewN/AView Earnings Details
3/10/2017Q4 2016($0.45)($0.52)$0.48 million$0.51 millionViewN/AView Earnings Details
11/9/2016Q316($0.50)($0.39)$0.47 million$0.48 millionViewListenView Earnings Details
8/9/2016Q216($0.49)($0.46)$0.55 million$0.44 millionViewListenView Earnings Details
5/10/2016Q116($0.43)($0.44)$458.00 millionViewListenView Earnings Details
3/10/2016Q415($0.47)($0.43)$0.44 millionViewListenView Earnings Details
11/10/2015Q315($0.38)($0.47)$0.43 millionViewListenView Earnings Details
8/10/2015Q215($0.33)($0.45)$0.46 millionViewListenView Earnings Details
5/15/2015Q115($0.39)($0.35)$0.30 million$0.43 millionViewListenView Earnings Details
3/10/2015Q4($0.38)($0.37)$0.20 million$0.51 millionViewListenView Earnings Details
11/12/2014Q3 14($0.55)($0.48)$0.10 million$0.14 millionViewListenView Earnings Details
8/28/2014Q2 2014($2.31)($2.10)$0.10 million$0.10 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Ocular Therapeutix (NASDAQ:OCUL) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Ocular Therapeutix (NASDAQ OCUL) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 15.90%
Institutional Ownership Percentage: 54.80%
Insider Trading History for Ocular Therapeutix (NASDAQ:OCUL)
Institutional Ownership by Quarter for Ocular Therapeutix (NASDAQ:OCUL)

Ocular Therapeutix (NASDAQ OCUL) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/12/2017Antony C MattessichInsiderBuy21,000$4.29$90,090.0021,000View SEC Filing  
12/7/2017Donald NotmanCFOBuy4,800$4.00$19,200.004,800View SEC Filing  
12/6/2017Daniel M BollagInsiderBuy24,700$3.93$97,071.0024,700View SEC Filing  
11/16/2017Amarpreet SawhneyChairmanBuy19,000$5.18$98,420.00696,390View SEC Filing  
12/15/2016Amarpreet SawhneyInsiderBuy45,300$7.85$355,605.00677,390View SEC Filing  
6/9/2016Amarpreet SawhneyCEOBuy10,000$6.70$67,000.00573,733View SEC Filing  
11/17/2015Amarpreet SawhneyCEOBuy10,000$8.25$82,500.00563,733View SEC Filing  
9/15/2015James FortuneCOOSell9,470$17.16$162,505.20112,060View SEC Filing  
9/14/2015Amarpreet SawhneyCEOBuy15,000$16.50$247,500.00553,733View SEC Filing  
6/15/2015Charles M WardenDirectorSell320,000$22.00$7,040,000.00View SEC Filing  
6/10/2015Charles M WardenDirectorSell427,000$22.00$9,394,000.00View SEC Filing  
6/10/2015Svlsf Iv, LlcMajor ShareholderSell1,119,000$22.00$24,618,000.00View SEC Filing  
7/30/2014Amarpreet SawhneyCEOBuy76,922$13.00$999,986.00View SEC Filing  
7/30/2014Svlsf Iv, LlcMajor ShareholderBuy715,380$13.00$9,299,940.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Ocular Therapeutix (NASDAQ OCUL) News Headlines

Source:
DateHeadline
Zacks Investment Research Lowers Ocular Therapeutix (OCUL) to SellZacks Investment Research Lowers Ocular Therapeutix (OCUL) to Sell
www.americanbankingnews.com - May 12 at 10:38 AM
Cantor Fitzgerald Reiterates Overweight on Ocular Therapeutix (OCUL) Following 1QCantor Fitzgerald Reiterates Overweight on Ocular Therapeutix (OCUL) Following 1Q
www.streetinsider.com - May 11 at 5:57 PM
Edited Transcript of OCUL earnings conference call or presentation 8-May-18 8:30pm GMTEdited Transcript of OCUL earnings conference call or presentation 8-May-18 8:30pm GMT
finance.yahoo.com - May 10 at 8:25 AM
Ocular Therapeutix (OCUL) Receives Average Rating of "Buy" from BrokeragesOcular Therapeutix (OCUL) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - May 10 at 3:48 AM
Ocular Therapeutix (OCUL) Releases  Earnings Results, Misses Expectations By $0.02 EPSOcular Therapeutix (OCUL) Releases Earnings Results, Misses Expectations By $0.02 EPS
www.americanbankingnews.com - May 9 at 10:28 PM
Ocular Therapeutix (OCUL) Given a $10.00 Price Target at HC WainwrightOcular Therapeutix (OCUL) Given a $10.00 Price Target at HC Wainwright
www.americanbankingnews.com - May 9 at 5:12 PM
Ocular Therapeutixs (OCUL) CEO Antony Mattessich on Q1 2018 Results - Earnings Call TranscriptOcular Therapeutix's (OCUL) CEO Antony Mattessich on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 9 at 8:19 AM
Ocular Therapeutix (OCUL) Given a $22.00 Price Target at Cantor FitzgeraldOcular Therapeutix (OCUL) Given a $22.00 Price Target at Cantor Fitzgerald
www.americanbankingnews.com - May 8 at 6:26 PM
BRIEF-Ocular Therapeutix Reports Q1 Loss Per Share $0.40BRIEF-Ocular Therapeutix Reports Q1 Loss Per Share $0.40
www.reuters.com - May 8 at 5:38 PM
Ocular Therapeutix: 1Q Earnings SnapshotOcular Therapeutix: 1Q Earnings Snapshot
finance.yahoo.com - May 8 at 5:38 PM
Ocular Therapeutix™ Reports First Quarter 2018 Financial Results and Business UpdateOcular Therapeutix™ Reports First Quarter 2018 Financial Results and Business Update
finance.yahoo.com - May 8 at 5:38 PM
Ocular Therapeutix™ Announces Treatment of First Patient in Phase 1 Clinical Trial of OTX-TIC (travoprost intracameral implant) for the Treatment of Glaucoma and Ocular ...Ocular Therapeutix™ Announces Treatment of First Patient in Phase 1 Clinical Trial of OTX-TIC (travoprost intracameral implant) for the Treatment of Glaucoma and Ocular ...
www.businesswire.com - May 3 at 5:24 PM
Ocular Therapeutix™ Announces Treatment of First Patient in Phase 1 Clinical Trial of OTX-TIC (travoprost intracameral implant) for the Treatment of Glaucoma and Ocular HypertensionOcular Therapeutix™ Announces Treatment of First Patient in Phase 1 Clinical Trial of OTX-TIC (travoprost intracameral implant) for the Treatment of Glaucoma and Ocular Hypertension
finance.yahoo.com - May 3 at 5:24 PM
Ocular Therapeutix™ to Present Data at the Association for Research in Vision and Ophthalmology (ARVO) Annual ...Ocular Therapeutix™ to Present Data at the Association for Research in Vision and Ophthalmology (ARVO) Annual ...
www.businesswire.com - April 28 at 8:30 AM
Ocular Therapeutix™ to Report First Quarter 2018 Financial ResultsOcular Therapeutix™ to Report First Quarter 2018 Financial Results
finance.yahoo.com - April 26 at 5:16 PM
Ocular Therapeutix (OCUL) Set to Announce Earnings on ThursdayOcular Therapeutix (OCUL) Set to Announce Earnings on Thursday
www.americanbankingnews.com - April 26 at 2:34 AM
Ocular Therapeutix (OCUL) Stock Rating Lowered by ValuEngineOcular Therapeutix (OCUL) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - April 19 at 2:24 PM
Ocular Therapeutix (OCUL) PT Set at $35.00 by Cantor FitzgeraldOcular Therapeutix (OCUL) PT Set at $35.00 by Cantor Fitzgerald
www.americanbankingnews.com - April 19 at 12:16 PM
Quotidian Technical Highlights on Selected Biotech Stocks -- Ocular Therapeutix, Onconova Therapeutics, OPKO ...Quotidian Technical Highlights on Selected Biotech Stocks -- Ocular Therapeutix, Onconova Therapeutics, OPKO ...
www.prnewswire.com - April 17 at 8:31 AM
Ocular Therapeutix (OCUL) Stock Rating Upgraded by ValuEngineOcular Therapeutix (OCUL) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - April 16 at 7:35 PM
Ocular Therapeutix Inc (OCUL) Given Average Rating of "Buy" by AnalystsOcular Therapeutix Inc (OCUL) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - April 15 at 3:25 AM
Ocular Therapeutix (OCUL) Given a $10.00 Price Target by HC Wainwright AnalystsOcular Therapeutix (OCUL) Given a $10.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - April 14 at 10:05 AM
Ocular Therapeutix (OCUL) Rating Reiterated by HC WainwrightOcular Therapeutix (OCUL) Rating Reiterated by HC Wainwright
www.americanbankingnews.com - April 11 at 11:52 PM
Ocular Therapeutix (OCUL) Earns "Neutral" Rating from BTIG ResearchOcular Therapeutix (OCUL) Earns "Neutral" Rating from BTIG Research
www.americanbankingnews.com - April 11 at 5:00 PM
Ocular Therapeutix™ to Present Data at the American Society of Cataract and Refractive Surgery (ASCRS) SymposiumOcular Therapeutix™ to Present Data at the American Society of Cataract and Refractive Surgery (ASCRS) Symposium
finance.yahoo.com - April 9 at 5:21 PM
Biotechs Take the Lead This MorningBiotechs Take the Lead This Morning
finance.yahoo.com - April 9 at 5:21 PM
Ocular Therapeutix (OCUL) Downgraded by Zacks Investment Research to "Sell"Ocular Therapeutix (OCUL) Downgraded by Zacks Investment Research to "Sell"
www.americanbankingnews.com - April 5 at 5:46 PM
Is There Now An Opportunity In Ocular Therapeutix Inc (NASDAQ:OCUL)?Is There Now An Opportunity In Ocular Therapeutix Inc (NASDAQ:OCUL)?
finance.yahoo.com - April 3 at 5:35 PM
ValuEngine Upgrades Ocular Therapeutix (OCUL) to SellValuEngine Upgrades Ocular Therapeutix (OCUL) to Sell
www.americanbankingnews.com - March 31 at 12:42 PM
Ocular Therapeutix (OCUL) Rating Increased to Hold at BidaskClubOcular Therapeutix (OCUL) Rating Increased to Hold at BidaskClub
www.americanbankingnews.com - March 24 at 1:17 PM
OCULAR THERAPEUTIX INCOCULAR THERAPEUTIX INC
www.finanznachrichten.de - March 23 at 5:42 PM
Ocular Therapeutix™ To Present at the HC Wainwright Annual Global Life Sciences Conference in Monte Carlo ... - Business Wire (press release)Ocular Therapeutix™ To Present at the HC Wainwright Annual Global Life Sciences Conference in Monte Carlo ... - Business Wire (press release)
www.businesswire.com - March 22 at 5:35 PM
Ocular Therapeutix™ To Present at the H.C. Wainwright Annual Global Life Sciences Conference in Monte Carlo, Monaco on April 8-10, 2018Ocular Therapeutix™ To Present at the H.C. Wainwright Annual Global Life Sciences Conference in Monte Carlo, Monaco on April 8-10, 2018
finance.yahoo.com - March 22 at 5:35 PM
Can the Rally in Ocular Therapeutix (OCUL) Shares Continue? - NasdaqCan the Rally in Ocular Therapeutix (OCUL) Shares Continue? - Nasdaq
www.nasdaq.com - March 22 at 8:26 AM
Can the Rally in Ocular Therapeutix (OCUL) Shares Continue?Can the Rally in Ocular Therapeutix (OCUL) Shares Continue?
finance.yahoo.com - March 22 at 8:26 AM
Ocular Therapeutix Inc (OCUL) Given Consensus Recommendation of "Buy" by AnalystsOcular Therapeutix Inc (OCUL) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - March 21 at 3:46 AM
Edited Transcript of OCUL earnings conference call or presentation 8-Mar-18 1:30pm GMTEdited Transcript of OCUL earnings conference call or presentation 8-Mar-18 1:30pm GMT
finance.yahoo.com - March 18 at 8:18 AM
Global ocular drug delivery technology market is expected to be driven by increasing prevalence of eye diseasesGlobal ocular drug delivery technology market is expected to be driven by increasing prevalence of eye diseases
www.marketwatch.com - March 16 at 6:29 PM
Ocular Therapeutix Inc (NASDAQ:OCUL): Are Analysts Optimistic?Ocular Therapeutix Inc (NASDAQ:OCUL): Are Analysts Optimistic?
finance.yahoo.com - March 16 at 8:21 AM
Equities Analysts Issue Forecasts for Ocular Therapeutix Incs FY2018 Earnings (OCUL)Equities Analysts Issue Forecasts for Ocular Therapeutix Inc's FY2018 Earnings (OCUL)
www.americanbankingnews.com - March 14 at 9:51 AM
Ocular Therapeutix (OCUL) Raised to "Buy" at Zacks Investment ResearchOcular Therapeutix (OCUL) Raised to "Buy" at Zacks Investment Research
www.americanbankingnews.com - March 13 at 10:45 AM
Ocular Therapeutix (OCUL) Earns "Buy" Rating from BTIG ResearchOcular Therapeutix (OCUL) Earns "Buy" Rating from BTIG Research
www.americanbankingnews.com - March 11 at 12:40 PM
Ocular Therapeutix (OCUL) PT Set at $22.00 by Cantor FitzgeraldOcular Therapeutix (OCUL) PT Set at $22.00 by Cantor Fitzgerald
www.americanbankingnews.com - March 8 at 7:03 PM
Under SEC scrutiny, Bedford’s Ocular Therapeutix plans FDA do-overUnder SEC scrutiny, Bedford’s Ocular Therapeutix plans FDA do-over
finance.yahoo.com - March 8 at 6:42 PM
Ocular Therapeutix (OCUL) Issues Quarterly  Earnings Results, Beats Expectations By $0.08 EPSOcular Therapeutix (OCUL) Issues Quarterly Earnings Results, Beats Expectations By $0.08 EPS
www.americanbankingnews.com - March 8 at 2:29 PM
Form 8-K OCULAR THERAPEUTIX, INC For: Mar 08 - StreetInsider.comForm 8-K OCULAR THERAPEUTIX, INC For: Mar 08 - StreetInsider.com
www.streetinsider.com - March 8 at 8:24 AM
Want To Invest In Ocular Therapeutix Inc (NASDAQ:OCUL)? Here’s How It Performed LatelyWant To Invest In Ocular Therapeutix Inc (NASDAQ:OCUL)? Here’s How It Performed Lately
finance.yahoo.com - March 8 at 8:24 AM
Ocular Therapeutix™ Reports Fourth Quarter and Year End 2017 Financial Results and Business UpdateOcular Therapeutix™ Reports Fourth Quarter and Year End 2017 Financial Results and Business Update
finance.yahoo.com - March 8 at 8:24 AM
Ocular Therapeutix (OCUL) Scheduled to Post Quarterly Earnings on ThursdayOcular Therapeutix (OCUL) Scheduled to Post Quarterly Earnings on Thursday
www.americanbankingnews.com - March 1 at 2:08 AM
Ocular Therapeutix™ to Present at the Cowen and Company 38th Annual Health Care Conference - Business Wire (press release)Ocular Therapeutix™ to Present at the Cowen and Company 38th Annual Health Care Conference - Business Wire (press release)
www.businesswire.com - February 28 at 8:18 AM

SEC Filings

Ocular Therapeutix (NASDAQ:OCUL) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Ocular Therapeutix (NASDAQ:OCUL) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Ocular Therapeutix (NASDAQ OCUL) Stock Chart for Tuesday, May, 22, 2018

Loading chart…

This page was last updated on 5/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.